2 citations
,
January 2018 in “Elsevier eBooks” Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.
2 citations
,
January 2023 in “Anais Brasileiros de Dermatologia” 3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery”
April 2019 in “Radiotherapy and oncology” HPV infection is linked to better survival in advanced anal cancer, higher radiation doses improve survival, especially in HPV-negative patients, and prostaglandin E₂ pretreatment can protect mouse hair follicles from radiation damage.
12 citations
,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
168 citations
,
December 1986 in “Cancer Chemotherapy and Pharmacology” Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.
1 citations
,
April 2004 in “Cancer” Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.
8 citations
,
May 2017 in “Singapore Medical Journal” A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
4 citations
,
November 2020 in “Acta Dermato Venereologica” Tofacitinib effectively improved severe skin symptoms in a patient with Hypohidrotic Ectodermal Dysplasia.
32 citations
,
July 2017 in “Oncotarget” Alternating treatment with two drugs could help cells in a rapid aging disease.
The treatment was ineffective in humans.
October 2018 in “Annals of oncology” Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.
8 citations
,
December 2023 in “International Journal of Molecular Sciences” Lower TNF-α levels in PRP may predict better treatment outcomes for bladder conditions.
18 citations
,
January 2021 in “Theranostics” The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
3 citations
,
May 2024 in “Diseases of the Colon & Rectum” Adding platelet-rich plasma does not improve healing of certain fistulas.
December 2025 in “Scientific Reports” Valproic acid helps hair follicle stem cells survive better in low oxygen and glucose conditions.
November 2016 in “Therapeutic Delivery” New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.
15 citations
,
January 2024 in “The AAPS Journal” 50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
10 citations
,
June 2018 in “Aaps Pharmscitech” The flutamide-loaded hydrogel is a promising, skin-friendly treatment for acne and hair loss, potentially requiring less frequent application.
1 citations
,
March 2019 in “Actas Dermo-Sifiliográficas” New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
15 citations
,
February 2021 in “Scientific Reports” RNA aptamers can specifically block FGF5-related cell growth, potentially treating related diseases or hair disorders.
3 citations
,
October 2012 in “DOAJ (DOAJ: Directory of Open Access Journals)” Pemetrexed with cisplatin is safer and more effective than gemcitabine with cisplatin for advanced lung cancer.
24 citations
,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
15 citations
,
January 2019 in “Journal of the Formosan Medical Association” Adalimumab helped control a child's severe eye disease when other treatments failed.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
44 citations
,
April 2006 in “Expert opinion on drug safety” Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.
53 citations
,
November 2014 in “International Journal of Oncology” Wedelolactone may help prevent bone damage in breast cancer by blocking certain cell signals.